tetano
Editor, Senior Moderator
Am Heart J Plus
. 2022 Jan;13:100113.
doi: 10.1016/j.ahjo.2022.100113. Epub 2022 Mar 5.
Cardiogenic shock temporally associated with COVID-19 vaccination after prior COVID-19 infection: A case report
Elizabeth M Jean-Marie[SUP] 1 2 [/SUP], Aya Tabbalat[SUP] 1 2 [/SUP], Chad Raymond[SUP] 1 2 [/SUP], Meisam Moghbelli[SUP] 1 2 [/SUP], Keith Armitage[SUP] 1 2 [/SUP], Ian J Neeland[SUP] 1 2 [/SUP]
Affiliations
Abstract
The introduction of coronavirus 2019 (COVID-19) vaccination has been an integral force in stopping the spread of COVID-19 across the globe. While reported side effects of vaccination have predominantly been mild, in the last year reports have emerged of myocarditis following the BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) vaccinations. The adolescent and young adult population have been the population most reported, with over 1000 cases under review by the Centers for Disease Control (CDC) since April 2021. Here we report a case of a previously healthy 21-year-old male who developed Multisystem Inflammatory Syndrome in Adults (MIS-A) and following the second dose of the Pfizer-BioNtech vaccine. The young male initially presented with fever, leukocytosis with high neutrophil-lymphocyte ratio, severe cardiac illness, and positive COVID-19 nucleocapsid serology, consistent with MIS-A diagnosis. His case was complicated by cardiogenic shock, requiring brief venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. While this report does not detract from the overwhelming benefit of vaccination from COVID-19, clinicians should be aware of this possible relationship in the future.
Keywords: Coronavirus 2019; Heart failure; MIS-A; MIS-C; Multisystem inflammatory syndrome in adults; Multisystem inflammatory syndrome in children.
. 2022 Jan;13:100113.
doi: 10.1016/j.ahjo.2022.100113. Epub 2022 Mar 5.
Cardiogenic shock temporally associated with COVID-19 vaccination after prior COVID-19 infection: A case report
Elizabeth M Jean-Marie[SUP] 1 2 [/SUP], Aya Tabbalat[SUP] 1 2 [/SUP], Chad Raymond[SUP] 1 2 [/SUP], Meisam Moghbelli[SUP] 1 2 [/SUP], Keith Armitage[SUP] 1 2 [/SUP], Ian J Neeland[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35282400
- PMCID: PMC8896859
- DOI: 10.1016/j.ahjo.2022.100113
Abstract
The introduction of coronavirus 2019 (COVID-19) vaccination has been an integral force in stopping the spread of COVID-19 across the globe. While reported side effects of vaccination have predominantly been mild, in the last year reports have emerged of myocarditis following the BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) vaccinations. The adolescent and young adult population have been the population most reported, with over 1000 cases under review by the Centers for Disease Control (CDC) since April 2021. Here we report a case of a previously healthy 21-year-old male who developed Multisystem Inflammatory Syndrome in Adults (MIS-A) and following the second dose of the Pfizer-BioNtech vaccine. The young male initially presented with fever, leukocytosis with high neutrophil-lymphocyte ratio, severe cardiac illness, and positive COVID-19 nucleocapsid serology, consistent with MIS-A diagnosis. His case was complicated by cardiogenic shock, requiring brief venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. While this report does not detract from the overwhelming benefit of vaccination from COVID-19, clinicians should be aware of this possible relationship in the future.
Keywords: Coronavirus 2019; Heart failure; MIS-A; MIS-C; Multisystem inflammatory syndrome in adults; Multisystem inflammatory syndrome in children.